CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Aug. 16, 2012--
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology
company with a current focus on the diagnosis and monitoring of cardiac
arrhythmias, announced today that CardioNet’s President and Chief
Executive Officer, Joseph Capper, has adopted a Rule 10b5-1 trading plan
to purchase shares of the Company’s common stock over time as part of
his individual investment strategy. The trading plan is being
established in accordance with Rule 10b5-1 under the Securities Exchange
Act of 1934 and CardioNet’s policies regarding stock transactions.
Rule 10b5-1 permits corporate officers and directors to adopt written,
pre-arranged stock trading plans when they are not in possession of
material, non-public information. Using these plans, insiders can
gradually adjust their investment portfolios and spread stock trades
over a period of time regardless of any material, non-public information
they may receive after adopting their plans. The transactions under
these plans will be disclosed publicly through Form 144 and Form 4
filings with the Securities and Exchange Commission.
Mr. Capper’s plan covers the purchase of up to 75,000 shares. Under the
terms of the plan, purchases can be made from time to time starting
August 17, 2012 through November 1, 2012 and may be amended in
accordance with the plan. The stock to be purchased will be acquired in
the open market.
About CardioNet
CardioNet is a leading provider of ambulatory, continuous, real-time
outpatient management solutions for monitoring relevant and timely
clinical information regarding an individual’s health. CardioNet's
initial efforts are focused on the diagnosis and monitoring of cardiac
arrhythmias, or heart rhythm disorders, with a solution that it markets
as Mobile Cardiac Outpatient TelemetryTM (MCOTTM).
More information can be found at http://www.cardionet.com.
Forward-Looking Statements
This document includes certain forward-looking statements within the
meaning of the “Safe Harbor” provisions of the Private Securities
Litigation Reform Act of 1995 regarding, among other things, our growth
prospects, the prospects for our products and our confidence in the
Company’s future. These statements may be identified by words such as
“expect,” “may,” “anticipate,” “possible,” “estimate,” “potential,”
“intend,” “plan,” “believe,” “forecast,” “promises” and other words and
terms of similar meaning. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any of
them, and could cause actual outcomes and results to differ materially
from current expectations. These factors include, among other things,
the effect of the cardioCORE acquisition on our business operations and
successful integration into our business, financial results,
effectiveness of our efforts to address operational initiatives,
including cost savings initiatives that affect our business, changes to
insurance coverage, relationships with our government and commercial
payors and reimbursement levels for our products, the success of our
sales and marketing initiatives, our ability to attract and retain
talented executive management and sales personnel, our ability to
identify acquisition candidates, acquire them on attractive terms and
integrate their operations into our business, the commercialization of
new products, market factors, internal research and development
initiatives, partnered research and development initiatives, competitive
product development, changes in governmental regulations and
legislation, the continued consolidation of payors, acceptance of our
new products and services and patent protection, adverse regulatory
action and litigation success. For further details and a discussion of
these and other risks and uncertainties, please see our public filings
with the Securities and Exchange Commission, including our latest
periodic reports on Form 10-K and 10-Q. We undertake no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise.
Source: CardioNet, Inc.
CardioNet, Inc.
Heather C. Getz
Investor Relations
800-908-7103
investorrelations@cardionet.com
